343604-08-0

Basic information

• Product Name: 3-{[3-(TRIFLUOROMETHYL)BENZYL]OXY}BENZALDEHYDE
• Synonyms: 3-{[3-(TRIFLUOROMETHYL)BENZYL]OXY}BENZALDEHYDE;3-{[3-(trifluoromethyl)benzyl]oxy}benzaldehyde(SALTDATA: FREE);IVK/4021484
• CAS NO: 343604-08-0
• Molecular Formula: C₁₅H₁₁F₃O₂
• Molecular Weight: 280.25
• Mol File: 343604-08-0.mol

Chemical Properties

• Boiling Point: 354.4°C at 760 mmHg
• Flash Point: 162.5°C
• Appearance: /
• Density: 1.277g/cm³
• Vapor Pressure: 3.37E-05mmHg at 25°C
• Refractive Index: 1.543
• CAS DataBase Reference: 3-{[3-(TRIFLUOROMETHYL)BENZYL]OXY}BENZALDEHYDE(CAS DataBase Reference)
• NIST Chemistry Reference: 3-{[3-(TRIFLUOROMETHYL)BENZYL]OXY}BENZALDEHYDE(343604-08-0)
• EPA Substance Registry System: 3-{[3-(TRIFLUOROMETHYL)BENZYL]OXY}BENZALDEHYDE(343604-08-0)

Safety Data

• Hazardous Substances Data: 343604-08-0(Hazardous Substances Data)

Usage

Uses

Used in Organic Synthesis:
3-[3-(TRIFLUOROMETHYL)BENZYL]OXYBENZALDEHYDE is utilized as a building block in organic synthesis for the creation of more complex molecules. Its unique structure allows for the development of a wide range of chemical compounds.
Used in Pharmaceutical Research:
In the pharmaceutical industry, 3-[3-(TRIFLUOROMETHYL)BENZYL]OXYBENZALDEHYDE is used as a research compound for the development of new drugs. Its properties make it a promising candidate for various medicinal applications.
Used in Agrochemicals:
3-[3-(TRIFLUOROMETHYL)BENZYL]OXYBENZALDEHYDE is also studied for its potential use in agrochemicals, where its unique properties can contribute to the development of effective and stable products for agricultural applications.
Used in Materials Science:
3-[3-(TRIFLUOROMETHYL)BENZYL]OXYBENZALDEHYDE has been investigated for its potential applications in materials science, where its structural and chemical characteristics can be harnessed to create new materials with specific properties.
Used in Chemical Industry:
3-[3-(TRIFLUOROMETHYL)BENZYL]OXYBENZALDEHYDE is valued in the chemical industry for its increased lipophilicity and stability, making it suitable for various applications that require these attributes.

InChI:InChI=1/C15H11F3O2/c16-15(17,18)13-5-1-4-12(7-13)10-20-14-6-2-3-11(8-14)9-19/h1-9H,10H2

Upstream product

• 402-23-3 1-bromomethyl-3-trifluoromethylbenzene 
• 99-06-9 3-Carboxyphenol 
• 100-83-4 meta-hydroxybenzaldehyde 

Relevant articles and documents

Phenolic compounds containing benzyloxy phenyl and preparation method and application of phenolic compounds

The invention discloses phenolic compounds (I) containing benzyloxy phenyl and a preparation method and application of the phenolic compounds. Pharmacological experiments prove that the phenolic compounds have high inhibiting activity on sphingosine kinase SphK, and part of the compounds has a certain inhibiting effect on inflammatory bowel disease induced by tumor and DSS. The phenolic compounds and the pharmaceutical preparations thereof can be used for preparing drugs for treating a series of cancer and inflammatory diseases such as colon cancer, lung cancer, breast cancer, liver cancer, stomach cancer, inflammatory bowel disease, hepatitis, asthma, chronic obstructive pulmonary disease, rheumatoid arthritis and multiple sclerosis.

Benzyloxynitrostyrene analogues – A novel class of selective and highly potent inhibitors of monoamine oxidase B

This study examines a series of novel 3-benzyloxy-β-nitrostyrene analogues as a novel class of inhibitors of the monoamine oxidase (MAO) enzymes. MAO inhibitors are considered useful for the treatment of depression and Parkinson's disease, and have recently attracted attention as potential therapeutic agents for a range of disorders including Alzheimer's disease, prostate cancer and certain cardiomyopathies. This study shows that the 3-benzyloxy-β-nitrostyrene analogues are potent inhibitors of the MAO-B isoform with IC50values in the nanomolar range (39–565 nM). Significantly, effectiveness towards MAO-B inhibition seems to be governed by the introduction of a 4″-fluoro-substituent on the benzyloxy ring, with compound 2b exhibiting the highest degree of MAO-B inhibition potency (IC50= 0.039 μM) and selectivity (SI = 166) among the compounds investigated. Since some of the 3-benzyloxy-β-nitrostyrene analogues possess potencies that are comparable to that of the reversible inhibitor, safinamide (IC50= 0.080 μM), it may be concluded that this class may be promising leads for the development of reversible and selective MAO-B inhibitors, that may be useful for the management of Parkinson's disease.

Development of hydroxy-based sphingosine kinase inhibitors and anti-inflammation in dextran sodium sulfate induced colitis in mice

Sphingosine kinase (SphK)-catalyzed production of sphingosine-1-phosphate (S1P) regulates cell growth, survival and proliferation as well as inflammatory status in animals. In recent study we reported the N′-(3-(benzyloxy)benzylidene)-3,4,5-trihydroxybenzohydrazide scaffold as a potent SphK inhibitor. As a continuation of these efforts, 51 derivatives were synthesized and evaluated by SphK1/2 inhibitory activities for structure-activity relationship (SAR) study. Among them, 33 was identified as the most potent SphK inhibitor. Potency of 33 was also observed to efficiently decrease SphK1/2 expression in human colorectal cancer cells (HCT116) and significantly inhibit dextran sodium sulfate (DSS)-induced colitis as well as the decreased expression of interleukin (IL)-6 and cyclooxygenase-2 (COX-2) in mouse models. Collectively, 33 was validated as an effective SphK inhibitor, which can be served as anti-inflammatory agent to probably treat inflammatory bowel diseases in human.

Discovery and SAR of hydrazide antagonists of the pituitary adenylate cyclase-activating polypeptide (PACAP) receptor type 1 (PAC1-R)

Potent small molecule antagonists for the PAC1-R have been discovered. Previously known antagonists for the PAC1-R were slightly truncated peptide ligands. The hydrazides reported here are the first small molecule antagonists ever reported for this class B GPCR.

Thrombopoietin mimetics

Invented are non-peptide TPO mimetics. Also invented is a method of treating thrombocytopenia, in a mammal, including a human, in need thereof which comprises administering to such mammal an effective amount of a selected substituted naphthimidazole derivative.